RxDoctor Payments Data

Deepak Grover, DO

Ophthalmology · Blue Bell, PANPI 1588808554

Payments from drug & device makers

$13,469in general payments, 2019–2025

Across 125 payments — averaging $107.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$11K
  • Alcon$1K
  • Carl Zeiss Meditec USA, Inc.$339
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$292
  • Bausch & Lomb Americas Inc.$230
  • Sight Sciences, Inc.$228
  • plus $681 from 11 others

What the payments were for

  • Speaking & faculty fees$9,77573%
  • Travel & lodging$540%
  • Food & beverage$3,62027%
  • Gifts$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,469 in reported general payments places this provider in the 85th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$333,478
Medicare patients
607
Services billed
2,220

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast32$38,454
RestasisCyclosporine44$34,802
LumiganBimatoprost48$26,701
TyrvayaVarenicline Tartrate12$11,649
Prednisolone Acetate274$9,905
RhopressaNetarsudil Mesylate19$9,366
Cyclosporine32$8,940
Travoprost29$6,338
RocklatanNetarsudil Mesylat/Latanoprost13$5,485
SimbrinzaBrinzolamide/Brimonidine Tart21$4,368
Dorzolamide-TimololDorzolamide/Timolol/Pf13$3,962
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat210$3,837
Difluprednate21$2,552
Latanoprost222$2,336
Brimonidine Tartrate130$2,123

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$88$61,50392 claims
Bausch & Lomb Americas Inc.Xiidra$230$38,45432 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$83$14,85132 claims
AlconSimbrinza$1,154$4,36821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 920 ophthalmology providers in Pennsylvania.

Other ophthalmology in Blue Bell

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →